TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Prostate-specific Antigen (PSA) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite measure of cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PPI-668 area under the curve from time zero to infinity (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPI-668 maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPI-668 area under the curve from time zero to the last quantifiable concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reports of risky behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Tensional auto-measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of objective progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paliperidone plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Understanding of their Medication Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of CVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intraocular pressures (IOP) lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentinal Hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PA-824 PK parameters area under the concentration-time curve (AUC) of 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 or higher signs and symptoms observed while on study and during the follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: PA-824 PK parameters Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cessation of Fever Within 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Fever Recurrence Within Next 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deviant fantasies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Re-infection with S. Aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Change in soluble CD14 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of subjects with treatment emergent adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: number of subjects with change in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exposure of galidesivir as measured by plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in WOMAC pain subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity of the serological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of acute treatment-associated adverse events ≥ grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive functioning assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pressure pain thresholds (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Overall Change in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age-appropriate immunization 12-23 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ORS use for diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sanitation Index
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Two-Point Light Spread Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Starburts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival Rate at Four Months (PFS4)
Endpoint domain: Mortality/survival
Primary endpoint: Pain relief (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral suppression at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Combined Skin Irritation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetics of Candesartan cilexetil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body weight in kilograms (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Melanin Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global domain of Cardiac Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical domain of Cardiac Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Emotional domain of Cardiac Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral assessment using PDDBI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Median time to 90% parasite clearance (PC90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Aortic pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in Augmentation index (AIx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Mental Health (BASIS-24 Summary Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maintenance of virological suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in glutamate level in target brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in gray matter volume in target brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: A/C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to GABA treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Pulsatility index of the uterine artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Physiologic Cost of Speaking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Oxygen Uptake Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Vocal Fatigue Index (VFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting Aortic Blood Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients undergoing the procedure without adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Enrichment of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: tolerability assessment
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Wound Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glucose area under the curve 0-240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating endothelial cells (CEC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lewis score area-under-the-curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function assessment questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain score questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anesthesia effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitization
Endpoint domain: Adverse events/effects
Primary endpoint: Blood sugar stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Events related to implant procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Time of the first analgesia request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from atrial fibrillation or other atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pocket Probing Depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Non-Ocular Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Score on the Delis-Kaplan Executive Function System (D-KEFS) Tower Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on Conners Continuous Performance Task Third Edition (CPT-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment late luminal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sex hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brain activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Investigator scar assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient scar assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Independent scar assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in brachial artery flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in vasodilation and vasoconstriction related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total area under the curve (AUC from 0 to infinity [AUC0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak cefixime level (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Failure (Loss of Glycemic Control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain associated with LNG-IUS insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AV fistula success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic control - HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic control - Fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic control - 2h-plasma glucose (2h-PG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic control - Fasting blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity - hepatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologically active doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daily Average Pain Over the Last 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum periostin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apolipoprotein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurocognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of severe fluoropyrimidine-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to depressed event
Endpoint domain: Mortality/survival
Primary endpoint: Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target Lesion Failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of antibiotics therapy in hospital
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma P-selectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Tx-M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary prostaglandin I2 (PGI-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with clinically relevant changes in electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with clinically relevant changes in pharmaco electroencephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with clinically relevant changes in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Th1/Th2 Normalized Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Does it recur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average daily uptime (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood content differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic, pancreatic and myocardial lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in insulin sensitivity and secretion via OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endometrial Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Area under the glucose infusion rate curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: False Negative Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between estimated gestational age and combined transcerebellar diameter and placental thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: neurofunctional outcome using Glasgow Outcome Scale (GOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neurofunctional outcome using modified Rankin Scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Simon task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of factors influencing paternal involvement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Progression of actinic keratosis or invasive squamous cell carcinoma (SCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence/reoccurrence of neoplastic skin tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in pediatric health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline SCAT-5 symptom score immediately after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline SCAT-5 symptom severity immediately after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Cervical Range of Motion immediately after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children´s Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual Function Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care-giver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Post-operative sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of fevers of unknown origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of each disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Proliferation Index (Ki-67) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of the use of the prone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Enumeration of CD4 and CD8 T Cell Responses to MAGE-A3 Epitopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post endodontic pain measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes